Nadolol is a b-adrenergic antagonist that has been shown to be efficacious in the treatment
of infantile hemangioma. It has been suggested that this drug may have fewer side effects
compared with the gold standard therapy, propranolol, because it does not exhibit
membrane-stabilizing effects and has little ability to cross the blood-brain barrier. However,
the pharmacokinetics and safety of nadolol in infants are not well understood, potentially
making this therapy dangerous. b-adrenergic antagonist toxicity causes bradycardia …